Asset Details
Do you wish to reserve the book?
The inactivated and ISA 61 VG adjuvanted vaccine enhances protection against cross-serotype Listeria monocytogenes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The inactivated and ISA 61 VG adjuvanted vaccine enhances protection against cross-serotype Listeria monocytogenes
Do you wish to request the book?
The inactivated and ISA 61 VG adjuvanted vaccine enhances protection against cross-serotype Listeria monocytogenes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The inactivated and ISA 61 VG adjuvanted vaccine enhances protection against cross-serotype Listeria monocytogenes
2025
Overview
Listeriosis is a zoonotic disease caused by
Listeria monocytogenes
(Lm), posing a significant threat to the breeding industry and public health. Ruminant livestock are particularly susceptible to Lm, thus effective strategies are needed for controlling ovine listeriosis. In this study, we developed two inactivated vaccines and evaluated their efficacy against Lm infection in murine and ovine models. We inactivated the Lm serotype 4h XYSN strain and adjuvanted it with water-in-oil ISA 61 VG (61 VG-AIV) or aluminum (Al-AIV). Pathological observations confirmed the safety of both vaccines in mice and sheep. The immunological assays demonstrated that, compared with the Al-AIV, the 61 VG-AIV induced higher levels of Lm-specific antibodies and proinflammatory cytokines, suggesting that the ISA 61 VG adjuvant has superior immunostimulatory effects compared with the alum adjuvant. 61 VG-AIV elicited greater immunoprotection than Al-AIV (83.4% vs. 50%) against serotype 4h Lm strain challenge in mice. Additionally, 61 VG-AIV afforded cross-protection against challenges with serotypes 1/2a, 1/2b, and 4b Lm strains. Importantly, high immunoprotection in sheep was conferred by the 61 VG-AIV group (83.4%). Taken together, our findings demonstrate that the ISA 61 VG adjuvant contributes to enhancing the humoral and cellular immune responses of inactivated Lm, and 61 VG-AIV is a promising vaccine candidate for the prevention and control of animal listeriosis. This research lays a solid foundation for its application in veterinary medicine.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
adjuvanted inactivated vaccine (AIV)
/ Adjuvants, Immunologic - administration & dosage
/ Adjuvants, Immunologic - pharmacology
/ Adjuvants, Vaccine - administration & dosage
/ alum
/ aluminum
/ Animals
/ Bacterial Vaccines - administration & dosage
/ Bacterial Vaccines - immunology
/ Female
/ industry
/ Listeria
/ Listeria monocytogenes - immunology
/ Listeriosis - prevention & control
/ Medicine
/ Mice
/ Sheep
/ Sheep Diseases - microbiology
/ Sheep Diseases - prevention & control
/ Vaccines
/ Vaccines, Inactivated - administration & dosage
/ Vaccines, Inactivated - immunology
/ Veterinary Medicine/Veterinary Science
/ Virology
/ Zoonoses
